Biologics License Application for 21-Valent Pneumococcal Vaccine Granted FDA Priority Review
Pharmaceutical Commerce
DECEMBER 19, 2023
Merck’s Biologics License Application for V116, a 21-valent pneumococcal conjugate vaccine, was given a Prescription Drug User Fee Act (PDUFA) date of June 17, 2024.
Let's personalize your content